AACC’s Clinical Pathology Laboratory Exhibition Showcases New Technology and Greater Interest in Lab Testing
Many new in vitro diagnostics companies show their products last week in Anaheim
It’s a troubling fact that most health policymakers in the public and private sectors continue to handle clinical pathology laboratory testing as a commodity. That often translates into health insurance programs paying medical laboratories ever less money for the tests they provide. Under-reimbursement for lab tests is a threat to the integrity of laboratory medicine in this country.
However, two groups in our country think differently than this group of health policymakers. These are patients and Wall Street investors. Individuals in both groups are closely tracking advances in laboratory testing and laboratory medicine that positively affect patient care. They know the clinical and economic benefit of using new clinical lab test technology for the right patient at the right time.
